FarrellREspandinMLakdawalaN. Incorporation of an Interferon beta neutralising antibody assay into routine clinical practice. Mult Scler [THIS ISSUE].
2.
UzeéGDi MarcoSMouchel-Vielh. Domains of interaction between alphainterferon and its receptor components. J Mol Biol1994; 243: 245–257.
3.
CheriyathVLeamanDWBordenEC. Emerging roles of FAM14 familymembers (G1P3/ISG 6–16 and ISG12/IFI27) in innate immunity and cancer. J Interferon Cytokine Res2011; 31: 173–181.
4.
GoodinDSFrohmanEMHurwitzB. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2007; 68: 977–984.
5.
PachnerARPolmanCHDeisenhammerF. Neutralizing antibodies tointerferon beta: assessment of their clinical and radiographic impact: an evidencereport: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2007; 69: 1552–1556.
6.
GoodinDSHurwitzBNoronhaA. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res2007; 35: 173–187.
7.
FarrellRBendtzenKBertolottoA. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res2008; 36: 204–210.
8.
GravesRM. Survey Errors and Survey Costs. New York: John Wiley and Sons, 1989.
9.
LamRFarrellRAzizT. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods2008; 336: 113–118.
10.
PrenticeRL. Surrogate endpoints in clinical trials: Definition and operationalcriteria. Stat Med1989; 8: 431–440.
